Jeffrey Goldberg

Jeffrey Goldberg

Plus aucun poste en cours

51 ans
Health Technology
Consumer Services
Finance

Profil

Jeffrey M.
Goldberg
served as President, Chief Executive Officer & Director at Spyre Therapeutics, Inc. in 2022-2023 and at Immunitas Therapeutics, Inc. in 2019-2021.
He was also the Chief Operating Officer at Akcea Therapeutics, Inc. from 2015 to 2019.
Prior to that, he was the Vice President of Business Operations at Proteostasis Therapeutics, Inc. from 2012 to 2014.
He also worked as the Senior Director of Product Operating Management at Genzyme Corp.
and as the Associate Vice President & Head of Project at Sanofi, Inc. Mr. Goldberg received a graduate degree from the Massachusetts Institute of Technology, an undergraduate degree from Cornell University, and an MBA from the MIT Sloan School of Management.

Anciens postes connus de Jeffrey Goldberg

SociétésPosteFin
SPYRE THERAPEUTICS, INC. Chief Executive Officer 16/05/2023
Chief Executive Officer 16/11/2021
AKCEA THERAPEUTICS, INC. Chief Operating Officer 23/09/2019
PROTEOSTASIS THERAPEUTICS, INC. Chief Operating Officer 01/01/2014
Corporate Officer/Principal -
Voir l'expérience en détail de Jeffrey Goldberg

Formation de Jeffrey Goldberg

Massachusetts Institute of Technology Graduate Degree
Cornell University Undergraduate Degree
MIT Sloan School of Management Masters Business Admin

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Jeffrey Goldberg

Relations

32

Relations au 1er degré

9

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées1
SPYRE THERAPEUTICS, INC.

Health Technology

Entreprise privées5

Health Technology

Retail Trade

Health Technology

Health Technology

Health Technology

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Jeffrey Goldberg